Covid-19 vaccination for children under five was hit by a delay of another month as US regulators abruptly put the brakes on their efforts to expedite the review of shots Pfizer is testing for youth. The Food and Drug Administration, concerned about the toll of the Omicron variant on children, took the extraordinary step of urging Pfizer to apply for an extra-low-dose vaccine before it was clear that the tots had to be given two doses. Will need a shot or three. The agency’s plan could allow vaccinations to begin within weeks.
But the FDA reversed course, saying it became clear the agency needed to wait for data on how well the third shot worked for the youngest group. Pfizer said in a statement that it expected to have the data by early April. The FDA’s vaccine chief, Dr. Peter Marks, said he hopes parents will understand that the agency’s decision was part of a careful scientific review of the evidence Pfizer has accumulated so far.
“That information made us realize we needed to look at data from the third dose from an ongoing trial,” Marks told reporters. “We take the responsibility of reviewing these vaccines very seriously because we are parents too.” The country’s 18 million children under the age of five are the only age group not yet eligible for vaccination.
China approves Pfizer oral tablet
China’s drug regulator has given conditional approval to import Pfizer’s PaxLovid Kovid-19 pill. The tablet is a small molecule oral drug, a co-package of the antiviral drugs nirmatrelavir tablets and ritonavir tablets, for adults who are experiencing mild to moderate COVID-19 symptoms and who are at high risk of becoming more critically ill. are at risk. China’s National Medical Products Administration said the pill could be given to patients who are older or have chronic kidney diseases, diabetes, heart disease and chronic lung diseases.
Total number of cases worldwide as of Saturday
total number of deaths worldwide
Worldwide patients cured till Saturday
Number of children under the age of five in the US
This story is taken from a third party syndicated feed, Agencies. Mid-Day accepts no responsibility or liability for its dependability, reliability, reliability and data of text. Mid-Day Management/Mid-Day.com reserves the sole right to change, remove or remove the Content (without notice) at its sole discretion for any reason.